Innovative antibody for

personalized medicine

About us

Skolkovo ResidentTheraMAB LLC is an emerging biopharmaceutical company developing  innovative, highly effective and broadly applicable immunotherapeutic monoclonal antibody. TheraMAB LLC focuses on the development of potential drug that, by its unique capacity to selectively modulate the activity of T-lymphocytes, may provide new treatment options for major diseases in the field of autoimmunity and cancer.
The Company was incorporated in August 2009 by the investment fund "Bioprocess Capital Ventures" and the German biotechnology company TheraMAB GmbH.